Safety First
Current cancer therapies are highly toxic. Most therapies are given intravenously and cause many unwanted side effects. It is important to the Reglagene team to develop orally available, well-tolerated medicines for patients to use in the comfort of their own homes. Reglagene can dose 200 mg/kg/day, equivalent to 80 Advil every day, in animal models without producing significant toxicity.

Well-Validated Target
Reglagene`s first development candidate inhibits a highly validated brain cancer target, previously inaccessible owing to the BBB. Many therapies and drug-delivery systems have tried and failed to access this target in patients. Reglagene has found a way to make this possible.

Blood–Brain Barrier Penetrant
Only 2% of all marketable drugs can cross the BBB, a filter that prevents toxins from entering the brain. The majority of medicines with this capability are pain and psychiatric medicines. Reglagene’s brain cancer medicine crosses the BBB and has nearly the same concentration in peripheral blood as in the brain.

Medicines For A Global Market
Reglagene accesses the advantages of what are known as small-molecule medicines. Benefits of small molecule medicines include: oral administration, low manufacturing costs, and well-traveled development and regulatory pathways.

Reglagene - Model RGNXXXX - Age Related Macular Degeneration for Microtubule Targeting Agent

Technical Data